ClinicalTrials.gg
RecruitingNCT05816733DETAIL-CMIVUpdated Nov 29, 2023

Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

A Phase 4 interventional study of Dapagliflozin and Placebo in Atrial Fibrillation Recurrence, Cox Maze IV and Atrial Fibrillation, sponsored by Kun Hua. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Kun Hua · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
96th of 256
348 · median 235
Started
2023
with 27 others
Phase 4
28 of 377
8 open now
Primary completion
2024-06
later than 7 of 182 live
Registered
189th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 96th largest by planned enrollment of the 256 interventional ones that give a count, is one of 28 that started in 2023, is one of 28 in phase 4, reaches primary completion later than 7 of the 182 other live ones, and was the 189th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common arrhythmia, which leads to reduced cardiac output and promotes the occurrence of heart failure, and abnormal hemodynamic changes in the left atrium induce thrombosis, which seriously reduces the quality of life, and even leads to death. For patients who need cardiac surgery combined with the Cox-Maze IV (CMIV) surgical ablation, oral amiodarone postoperatively for three consecutive months was recommended as the preferred treatment option. However, the study found there were still 15%-35% of patients at risk of AF recurrence. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been widely used for the treatment of type 2 diabetes mellitus and heart failure. Nonetheless, it remains unknown whether dapagliflozin can improve the recurrence of AF and reduces adverse cardiovascular events for patients who need CMIV ablation, and whether it can be routinely used for AF patients without diabetes or heart failure. Therefore, this study aims to explore the effect of postoperative oral dapagliflozin on the recurrence of AF after CMIV.

03

Conditions studied

  • Atrial Fibrillation Recurrence
  • Cox Maze IV
  • Atrial Fibrillation
  • Patients With or Without Heart Failure and Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Patients with persistent or long-term persistent atrial fibrillation who need isolated surgical Cox-Maze IV procedure
  • Patients who need cardiac surgery combined with Cox-Maze IV procedure
  • Patients who have the ability and willingness to abide by all the subsequent reviews and requirements
  • Sign the

Exclusion criteria

Exclusion Criteria:

  • Dapagliflozin allergy
  • Hyperthyroidism
  • Patients with acute myocardial infarction, cerebral apoplexy, and other vascular diseases during the past 6 months
  • Patients who received heart surgery within the last 3 months
  • \<45ml/min
  • History of oral SGLT2i
  • Estimated survival period \< 12 months
  • Pregnant and lactating women
  • Left atrial diameter > 65 mm
  • Refusing to sign the
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
348 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin group

    Patients who will be randomized to receive dapagliflozin following the Cox-Maze IV Procedure.

    Drug: Dapagliflozin

  • Placebo comparator
    Placebo group

    Patients who will be randomized to receive placebo following the Cox-Maze IV Procedure.

    Drug: Placebo

Interventions

  • Patients randomized in this arm will receive dapagliflozin at a target dose of 10mg once daily and routine treatment.

  • DrugPlacebo

    Patients randomized in this arm will receive placebo at a target dose of 10mg once daily and routine treatment.

06

What researchers measure

Primary outcomes

  1. Rate of atrial fibrillation recurrence

    Time frame: half of one year post operative

Secondary outcomes

  1. Rate of atrial fibrillation recurrence

    Time frame: one year post operative

  2. Cardiovascular complex adverse events

    cardiogenic death, new onset heart failure, malignant arrhythmias, stroke

    Time frame: one year post operative

07

Study locations

1 of 1 sites recruiting
  • Cardiac Surgery Center No. 7
    Beijing, Beijing 100029, China
    Recruiting
    • zhan peng · Contactanzhen0607@126.com · 01064456776
    • Hua Kun · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jun 2024, 9 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 9 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2023
First posted
Apr 18, 2023
StartActual
Sep 1, 2023
Primary completionEst.
Jun 7, 2024
CompletionEst.
Aug 7, 2024
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05816733
Lead sponsor
Kun Hua
Responsible party
Kun Hua (Clinical Professor, Beijing Anzhen Hospital) — Sponsor-investigator
First posted
Apr 18, 2023
Start date
Sep 1, 2023
Primary completion
Jun 7, 2024 (estimated)
Completion
Aug 7, 2024 (estimated)
Last update
Nov 29, 2023

Study contacts

Zhan Peng
Contact
anzhen0607@126.com
010-64456776
Xiubin Yang
Contact
xiubinyang@yahoo.com
010-64456776
Kun Hua
study director · Beijing Anzhen Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion